Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

ties, and investments to build greater breadth and capacity to support Schering-Plough's expanding R&D pipeline.

Acquired in-process research and development, a charge related to the purchase accounting of the OBS acquisition, totaled $3.8 billion for the fourth quarter of 2007.

Full-Year 2007 Results

For the full-year 2007, Schering-Plough reported a net loss available to common shareholders of $1.6 billion or $1.04 per common share on a GAAP basis due to purchase accounting adjustments. Earnings per common share would have been $1.37, excluding purchase accounting adjustments, acquisition-related items and other specified items (see table below on page 15). For the full- year 2006, Schering-Plough reported net income of $1.1 billion or 71 cents per common share on a GAAP basis and 87 cents per common share excluding other specified items.

Schering-Plough reported full-year 2007 GAAP net sales of $12.7 billion, a 20 percent increase, compared to $10.6 billion in 2006. Full-year 2007 net sales included $626 million of OBS net sales related to the period subsequent to the acquisition. In addition, the sales growth reflects a 4 percent favorable impact from foreign exchange. Schering-Plough's adjusted sales for 2007 totaled $15.2 billion, an increase of $2.7 billion as compared to $12.5 billion on an adjusted basis in 2006.

On a GAAP basis, Schering-Plough's gross margin was 65.3 percent in 2007 as compared to 65.1 percent in 2006. The gross margin percentage excluding purchase accounting adjustments and other specified items increased to 67.9 percent in 2007 as compared to 66.5 percent in 2006, due primarily to realized cost savings in 2007 from manufacturing streamlining activities during 2006.

Selling, general and administrative expenses were $5.5 billion for the 2007 full year. Research and development spending for 2007 totaled $2.9 billion. Full-year 2007 results include results of operations for OBS for the period subseq
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)... Queen,s University Belfast are developing new sen...hich will help in the fight against the threat of ...l gel pads to ,swipe, an individual or crime scene...anning instrument that can detect the presence of ...faster decisions to be made in response to terrori...
(Date:11/18/2009)...NE, Calif., Nov. 18 Ma...imetry(TM) and Measure-Through Motion and Low-Perf...rance-based Uni.H.A., one of the largest healthcar...has signed a multi-year purchasing agreement for "... The agreement offers preferred contract pricing ...
(Date:11/18/2009)...SSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM Bi... sciences product development company that identif...cancer-related products at various stages of devel...ting nimotuzumab were presented today in a poster ...ancer Therapeutics conference in Boston, Massachus...
(Date:11/18/2009)...111 significantly reduces key cardiac enzymes at m...esented at American Heart Association 2009 Scienti...e/ - Viron Therapeutics Inc., a biotechnology comp...g protein therapeutics derived from pathogens, tod...l evaluating VT-111 (Serp-1), an anti-inflammatory...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...wire-FirstCall/ -- China,Bionanometer Industries C...within the bionanometer industry has formally sign...ooperative partnership with China Guangzhou,LGLY A...s China,s top planning agency. It was,founded in D... advertising,professionals, its convergence of div...
...lows nanotechnology researchers at the National In...k the motions of nanoparticles in solution as they...hope the technology, which NIST plans to patent, w... of nanoparticles in fluids and, ultimately, proce...nanotech devices. , While some nanoscale fabricat...
...ipeline, Provides Critical API,s and ..., Idaho, March 10 RxElite, Inc. (OTC,Bulletin Boa... of specialty,generic prescription drug products, ... assets of FineTech Laboratories, Ltd. is complete...owned subsidiary of RxElite,under the name FineTec...
Other Biology Technology:CBIU Signs Agreement with LGLY Advertising LTD 2All done with mirrors: NIST microscope tracks nanoparticles in 3-D 2RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia 2
(Date:11/20/2009)...vailable in German . , In the current onlin..., Dr. Stefanie Eyerich and Dr. Kilian Eyerich toge...ondon and Istituto Dermopatico dell,Immacolata in ...epresents a milestone on the way to developing new...such as psoriasis and allergic reactions and poten...
(Date:11/20/2009)...e pulmonary disease (COPD), a respiratory disease ... is the fourth leading cause of death worldwide. ...chers have yet to find any real treatment or cure,...e University of Western Ontario in London, Canada,...nsight into the disease. , Parraga is a scie...
(Date:11/20/2009)...n a new study, researchers report that a class of ...helpful, or harmful, effect on the heart, dependin...h appears in the journal Circulation Research , f...- and beta-receptors on the heart muscle offer the...t target only the beta-receptors can actually unde...
Breaking Biology News(10 mins):Discovery of new type of immune cells regulating inflammation in chronic diseases 2Gaining a better picture of lung disease 2Carvedilol shown to have unique characteristics among beta blockers 2Once Again House Rejects Amendment Preventing Taxpayer Funding for Abortion 53394 1Once Again House Rejects Amendment Preventing Taxpayer Funding for Abortion 53394 2BBV Vietnam S E A Acquisition Corp Announces Signing of Letter of Intent for Business Combination with Migami Inc 53392 1BBV Vietnam S E A Acquisition Corp Announces Signing of Letter of Intent for Business Combination with Migami Inc 53392 2National League of Cities Commends President and Congress on Work Towards Health Care Reform 53390 1National League of Cities Commends President and Congress on Work Towards Health Care Reform 53390 2
...ontimber forest products industry has been growing...s of dollars to the U.S. economy annually. Example...les such as fruits and nuts, medicinal and herbal ...ucts. Standouts in the NTFP industry include U.S.-...mand for herbal medications. American ginseng, for...
...sland in Panama, home of the Smithsonian Tropical ...d station, has been described as the best-studied ...phere. Although the island has been a mecca for bi...ographed an elusive island visitor, the jaguarunti...kie Willis and her husband Greg mount cameras with...
... 4, 2009 -- Crop water use efficiency (WUE, or yie...er productivity, can be improved through irrigatio...tion (irrigating less than is required for maximum...o supplement precipitation so as to avoid crop fai...r agricultural production with limited water resou...
Other Biology News:Decreasing deer damage 2Decreasing deer damage 3First jaguar photo taken at Smithsonian Research Station in Panama 2Crop models help increase yield per unit of water used 2
Mouse Anti-beta-lactoglobulin Monoclonal Antibody, Unconjugated, Clone CD-2 from Cosmo Bio Co., Ltd.
...Anti-AP-2 α, clone 8G8/5 GenBank Accession ...uman AP-2alpha/gamma fusion protein corresponding ...ues 278-450 of human AP-2γ Formulation: 0.1M...ide before the addition of glycerol to 30% Quality...
MMP-2/MMP-9 Inhibitor IV [SB-3CT] from CHEMICON
Costar 6 Well Cell Culture Plate, 9.5 cm2, 34.8 mm Diam. Well, Sterile from Sigma-Aldrich
Biology Products: